Last reviewed · How we verify
Ceftazidime or meropenem
Ceftazidime and meropenem are broad-spectrum cephalosporin antibiotics that inhibit bacterial cell wall synthesis.
Ceftazidime and meropenem are broad-spectrum cephalosporin antibiotics that inhibit bacterial cell wall synthesis. Used for Nosocomial pneumonia, Complicated urinary tract infections.
At a glance
| Generic name | Ceftazidime or meropenem |
|---|---|
| Sponsor | Arrevus Inc. |
| Drug class | Cephalosporin antibiotic |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 2 |
Mechanism of action
They work by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, resulting in the disruption of the bacterial cell wall synthesis and ultimately leading to bacterial cell death.
Approved indications
- Nosocomial pneumonia
- Complicated urinary tract infections
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Cefotetan Therapy for Escherichia Coli Infections (PHASE2)
- Antibiotic Concentrations Among Critically Ill Patients
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections (PHASE3)
- The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring
- Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection (NA)
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Antimicrobial Resistance in Hospitals From Meta, Colombia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |